New Jersey-based pharmaceutical company Pacira Biosciences, Inc. (PCRX) has signed an agreement to acquire biopharmaceutical firm Flexion Therapeutics, Inc.
Pacira Biosciences reported preliminary net product sales in 1Q FY21 of Exparel (bupivacaine liposome injectable suspension) and iovera of $114.7 million and $3.
Pacira’s Exparel “Hit Where It Needed to Most” Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were falling 12% yesterday after the drug maker’s pain medicine …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced the publication of its Phase 4 PILLAR study of EXPAREL (bupivacaine liposome injectable suspension) in total knee arthroplasty (TKA). The …
Neuralstem Shares Collapse on Clinical Setback Shares of Neuralstem, Inc. (NASDAQ:CUR) were hit hard Tuesday after news that its MDD drug failed a …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) started 2017 strong, pre-announcing a fourth-quarter of 2017 beat coupled with full-year results that outclassed consensus expectations. The biotech …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced preliminary unaudited total revenues and EXPAREL (bupivacaine liposome injectable suspension) net product sales for the fourth quarter and …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a …
Investors who listened to Irina Rivkind Koffler over the past year have made 17 percent on their Koffler bets, according to TipRanks. The analyst, …
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results …